This is version 1.4 of the entry. See complete
history.
,
Johnson, L.C.,
Kridel, S.J.,
Lowther, W.T.(2007) Nat Struct Mol Biol 14: 704-709
Human fatty acid synthase (FAS) is uniquely expressed at high levels in many tumor types. Pharmacological inhibition of FAS therefore represents an important therapeutic opportunity. The drug Orlistat, which has been approved by the US Food and Drug Administration, inhibits FAS, induces tumor cell-specific apoptosis and inhibits the growth of prostate tumor xenografts. We determined the 2.3-A-resolution crystal structure of the thioesterase domain of FAS inhibited by Orlistat. Orlistat was captured in the active sites of two thioesterase molecules as a stable acyl-enzyme intermediate and as the hydrolyzed product. The details of these interactions reveal the molecular basis for inhibition and suggest a mechanism for acyl-chain length discrimination during the FAS catalytic cycle. Our findings provide a foundation for the development of new cancer drugs that target FAS.
Center for Structural Biology and Department of Biochemistry, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157, USA.
Macromolecule Content
Find similar proteins by:
(by identity cutoff) |
3D StructureExperimental Data & Validation
Experimental Data:
Length ( Å ) Angle ( ˚ ) a = 41.86 α = 90 b = 94.32 β = 95.82 c = 69.72 γ = 90 Software Package: Software Name Purpose REFMAC refinement CBASS data collection d*TREK data reduction d*TREK data scaling PHASER phasingRetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4